A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2022-09-10
Adverse events
Grade 3 Colitis — outcome: RECOVERED/RESOLVED; onset 2022-10-17 (study day 24); relationship: not assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-25 (study day 63); relationship: not assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-03-13 (study day 171); relationship: Y
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-08-17 (study day 328); relationship: not assessed
Grade 2 Neutropenia — outcome: UNKNOWN; onset 2023-10-14 (study day 386); relationship: N
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-12-20 (study day 453); relationship: N
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-12-25 (study day 458); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-01-02 (study day 466); relationship: not assessed
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-03-19 (study day 543); relationship: N
Data queries
No data queries.